VELOSEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELOSEF (VELOSEF).
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
| Metabolism | Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration and tubular secretion. |
| Excretion | Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); small biliary/fecal (5-10%) |
| Half-life | 1-2 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min) |
| Protein binding | 10-20% bound to serum albumin |
| Volume of Distribution | 0.3-0.5 L/kg (approximates extracellular fluid volume) |
| Bioavailability | Oral: 70-80% (capsule and suspension); IM: ~90% |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 15-30 minutes; Intravenous: within minutes |
| Duration of Action | 6-8 hours (normal renal function); extended in renal impairment; dose adjustment required |
| Molecular Weight | 349.41 |
250-500 mg orally every 6 hours or 1-2 g intramuscularly/intravenously every 6-12 hours for moderate to severe infections.
| Dosage form | TABLET |
| Renal impairment | GFR 10-30 mL/min: 250 mg every 12 hours; GFR <10 mL/min: 250 mg every 24 hours. |
| Liver impairment | No specific Child-Pugh based adjustments; use caution in severe hepatic impairment. |
| Pediatric use | 50-100 mg/kg/day orally divided every 6 hours; 50-100 mg/kg/day intramuscularly/intravenously divided every 6-12 hours. |
| Geriatric use | Dose based on renal function; reduce dose according to GFR as in renal adjustment. |
| 1st trimester | Avoid unless benefit outweighs risk. Cefradine crosses placenta; limited human data suggest low risk, but animal studies show no harm. However, consider alternative cephalosporins with more safety data. |
| 2nd trimester | Generally considered safe. No known teratogenic effects. Use for clear indications with standard dosing. |
| 3rd trimester | Generally considered safe. Monitor for potential adverse effects in neonate (e.g., diarrhea, rash) if maternal use near delivery. |
Clinical note
Comprehensive clinical and safety monograph for VELOSEF (VELOSEF).
| Placental transfer | Cefradine readily crosses the placenta. Detectable in fetal blood and amniotic fluid. Transfer is sufficient to achieve therapeutic levels in fetal tissues. |
| Breastfeeding | Cefradine is excreted into breast milk in small amounts. Levels are low and unlikely to cause adverse effects in a nursing infant. However, theoretical risks include alteration of infant gut flora, diarrhea, and allergic sensitization. Use with caution, especially in infants with known hypersensitivity or severe illness. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to cefradine or any cephalosporinHypersensitivity to penicillins (possible cross-allergy)
| Precautions | Hypersensitivity reactions: cross-allergenicity with penicillins and other cephalosporins, Pseudomembranous colitis: Clostridium difficile-associated diarrhea reported with nearly all antibacterial agents, Renal impairment: dosage adjustment required in patients with significantly reduced renal function, Seizure potential: use with caution in patients with a history of seizures, especially with high doses or renal impairment |
| Food/Dietary | No significant food interactions. May be taken with or without food. Avoid alcohol during treatment and for several days after to prevent disulfiram-like reaction (though rare with cephalosporins). |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Cephalosporins, including VELOSEF, are generally considered low risk in pregnancy. Animal studies have not shown fetal harm, but adequate human studies in pregnant women are lacking. In the first trimester, risk is not established; second and third trimesters are likely safe with no known teratogenic effects. FDA Pregnancy Category B. |
| Fetal Monitoring | Monitor for maternal adverse effects: gastrointestinal disturbances, hypersensitivity reactions, and superinfection. No specific fetal monitoring required unless maternal condition warrants. Renal function monitoring recommended in preeclampsia or gestational hypertension. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available; potential for reversible sperm motility inhibition with high doses (theoretical, not clinically significant). |
| Clinical Pearls | VELOSEF (cephradine) is a first-generation cephalosporin with activity against Gram-positive cocci (except MRSA and enterococci) and some Gram-negative rods. It is well-absorbed orally but has a short half-life, requiring frequent dosing. Dose adjustment is necessary in renal impairment (CrCl <20 mL/min). Cross-allergenicity with penicillins occurs in about 10% of patients. It is not effective against Pseudomonas or Bacteroides. |
| Patient Advice | Take this medication exactly as prescribed, usually every 6 or 12 hours, depending on the condition. · Finish the entire course even if you feel better to prevent antibiotic resistance. · If you have a penicillin allergy, inform your doctor before taking this medication. · Notify your doctor if you develop severe diarrhea, rash, or difficulty breathing. · Store at room temperature away from moisture and heat. |